<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01111279</url>
  </required_header>
  <id_info>
    <org_study_id>BTT-gpASIT004</org_study_id>
    <nct_id>NCT01111279</nct_id>
  </id_info>
  <brief_title>Clinical Safety and Tolerability Study of gpASIT+TM and gpASIT+TM/Immunoregulating Adjuvant to Treat Seasonal Grass Pollen Rhinoconjunctivitis</brief_title>
  <official_title>Clinical Safety and Tolerability of gpASIT+TM Administered Subcutaneously in Absence or in Presence of DnaK Immunoregulating Adjuvant for the Prophylaxis of Seasonal Grass Pollen Rhinoconjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioTech Tools S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioTech Tools S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of gpASIT+TM administered&#xD;
      subcutaneously in absence or in presence of an immunoregulating adjuvant in grass pollen&#xD;
      allergic patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical tolerability and safety of the treatment</measure>
    <time_frame>3 times during the treatment phase, at week 24 (the end of the study)</time_frame>
    <description>The following parameters will be assessed : general physical status, vital signs, haematological parameters , general blood biochemistry parameters, all (serious) adverse, immunological analysis (total IgG, total IgE) and inflammatory parameters (CRP, sedimentation rate)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of gpASIT+TM on the immunological status of the subjects</measure>
    <time_frame>visit 1, week 7, week 18 and week 24</time_frame>
    <description>The following parameters will be assessed :&#xD;
allergen-specific IgE, IgG, IgG4, IgA antibody concentrations,&#xD;
adjuvant-specific IgG antibody concentrations,&#xD;
lymphoproliferation and production of IL-10 in allergen and adjuvant stimulated PBMC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of gpASIT+TM on the clinical status of the subjects</measure>
    <time_frame>1 May - 15 August 2010</time_frame>
    <description>The following parameters will be assessed (during the pollen season following treatment):&#xD;
daily average allergic symptom score,&#xD;
daily average allergic medication score,&#xD;
number of &quot;well-days&quot;,&#xD;
Visual Analogue Scale .</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Seasonal Allergic Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>gpASIT+TM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>gpASIT+TM/adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gpASIT+TM</intervention_name>
    <description>1 subcutaneous injection every 7 days, during 29 days.</description>
    <arm_group_label>gpASIT+TM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gpAST+TM/adjuvant</intervention_name>
    <description>1 subcutaneous injection every 7 days, during 29 days</description>
    <arm_group_label>gpASIT+TM/adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo solution</intervention_name>
    <description>1 subcutaneous injection every 7 days, during 29 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has given written informed consent&#xD;
&#xD;
          -  Age between 18 and 50 years&#xD;
&#xD;
          -  The subjects are in good physical and mental health according to his/her medical&#xD;
             history, vital signs, and clinical status&#xD;
&#xD;
          -  Male or non pregnant, non-lactating female&#xD;
&#xD;
          -  Females unable to bear children must have documentation of such in the CRF (i.e.&#xD;
             tubule ligation, hysterectomy, or post menopausal (defined as a minimum of one year&#xD;
             since the last menstrual period))&#xD;
&#xD;
          -  Allergy diagnosis:&#xD;
&#xD;
               -  A history of seasonal allergic rhinoconjunctivitis (SAR) during the grass pollen&#xD;
                  season during at least during the two previous years&#xD;
&#xD;
               -  A positive skin prick test (wheal diameter ≥ 3 mm) to grass-pollen mixture&#xD;
&#xD;
               -  Specific IgE against grass pollen (RAST class 2 or IgE &gt; 0.7 kU/l)&#xD;
&#xD;
               -  Asymptomatic to perennial inhalant allergens even if shown to be hypersensitive&#xD;
                  in a skin prick test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with current or past immunotherapy (any time in the past)&#xD;
&#xD;
          -  A history of hypersensitivity to the excipients&#xD;
&#xD;
          -  Subjects requiring control medication against asthma (bronchodilator nebulised drugs&#xD;
             or local or systemic corticosteroids)&#xD;
&#xD;
          -  Subjects with documented evidence of acute or significant chronic sinusitis (as&#xD;
             determined by investigator)&#xD;
&#xD;
          -  Subjects with a history of hepatic or renal disease&#xD;
&#xD;
          -  Subjects symptomatic to perennial inhalant allergens&#xD;
&#xD;
          -  Subjects with rhinitis medicamentosa, non-specific rhinitis (to food dye, preservative&#xD;
             agent…)&#xD;
&#xD;
          -  Subject with malignant disease, autoimmune disease (and family medical history of&#xD;
             autoimmune disease)&#xD;
&#xD;
          -  Any chronic disease, which may impair the subject's ability to participate in the&#xD;
             trial (i.e. severe congestive heart failure, active gastric or duodenal ulcer,&#xD;
             uncontrolled diabetes mellitus, etc…)&#xD;
&#xD;
          -  Subjects requiring beta-blockers medication&#xD;
&#xD;
          -  Chronic use of concomitant medications that would affect assessment of the&#xD;
             effectiveness of the trial medication (e.g. tricyclic antidepressants)&#xD;
&#xD;
          -  Subject with febrile illness (&gt; 37.5°C, oral)&#xD;
&#xD;
          -  A known positive serology for HIV-1/2, HBs antigen or anti-HCV antibodies&#xD;
&#xD;
          -  The subject is immunocompromised by medication or illness, has received a vaccine,&#xD;
             corticoids or immunosuppressive medications within 1 month before trial entry&#xD;
&#xD;
          -  Receipt of blood or a blood derivative in the past 6 months preceding trial entry&#xD;
&#xD;
          -  Regular consumption of corticoids (oral, topic or nasal) or of anti-histaminic drugs&#xD;
             within 4 weeks preceding the trial&#xD;
&#xD;
          -  Any consumption of corticoids (oral, topic or nasal) or of anti-histaminic drugs&#xD;
             within 1 week preceding the trial&#xD;
&#xD;
          -  Use of long-acting antihistamines&#xD;
&#xD;
          -  Female subjects who are pregnant, lactating, or of child-bearing potential and not&#xD;
             protected from pregnancy by a sufficiently reliable method (OCs, IUD)&#xD;
&#xD;
          -  Any condition which could be incompatible with protocol understanding and compliance&#xD;
&#xD;
          -  Subjects who have forfeited their freedom by administrative or legal award or who are&#xD;
             under guardianship&#xD;
&#xD;
          -  Unreliable subjects including non-compliant subjects, subjects with known alcoholism&#xD;
             or drug abuse or with a history of a serious psychiatric disorder as well as subjects&#xD;
             unwilling to give informed consent or to abide by the requirements of the protocol&#xD;
&#xD;
          -  Subjects without means of contacting the investigator rapidly in case of emergency, or&#xD;
             not able to be contacted rapidly by the investigator&#xD;
&#xD;
          -  Participation in another clinical trial and/or treatment with an experimental drug&#xD;
             within 1 month of trial start&#xD;
&#xD;
          -  Subjects who participated to trial BTT-gpASIT003 and were in the treated groups&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Ceuppens, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Leuven, Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>April 20, 2010</study_first_submitted>
  <study_first_submitted_qc>April 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2010</study_first_posted>
  <last_update_submitted>February 28, 2011</last_update_submitted>
  <last_update_submitted_qc>February 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Thierry Legon / CEO</name_title>
    <organization>BioTech Tools</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

